Developer docs
API playgroundTry for free, no card

Search company profiles

Nordic Pharma

Full company profile

uuid000ariz

Namestring
Nordic Pharma
Legal namestring
Nordic Pharma, Inc.
Company typeenum
Private
Founded yearint
1995
Descriptiontext

Nordic Pharma, Inc. is the U.S. commercial arm of Nordic Group, a privately owned pan-European pharmaceutical company headquartered in Paris and founded in 1995. The U.S. entity is built around a single commercialized product, LACRIFILL Canalicular Gel, an FDA-cleared interventional therapy for dry eye disease that works by temporarily blocking tear drainage via a proprietary gel formulation delivered through prefilled syringes. The product received FDA clearance in May 2024 and was enhanced in April 2026 through the inclusion of cannulas in shipments, packaged in 10-pack cartons for direct distribution to U.S. eye care professionals.

The company has reported treating over 100,000 patients with LACRIFILL in under two years post-clearance, an adoption signal it actively promotes at specialty ophthalmology conferences including ASCRS 2026 in Washington D.C. Its go-to-market is an enterprise field sales motion targeting ophthalmologists, with quote-based pricing that is not publicly disclosed and a revenue model that functions as a one-time product sale per treatment. Leadership comprises Anders Lofgren (Founder, Managing Director & Vice President) and Jean-Michel Quinot (President). The firm operates as a privately held company with no disclosed institutional ownership, funding rounds, or M&A activity in the available record.

Short descriptiontext

Nordic Pharma is the U.S. arm of privately held Nordic Group, commercializing LACRIFILL Canalicular Gel — an FDA-cleared interventional dry eye therapy sold directly to ophthalmologists via enterprise field sales. The single-SKU product has treated over 100,000 U.S. patients since its May 2024 launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersHoofddorp, Netherlands
HQ citystring
Hoofddorp
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
dry eye treatment, ophthalmic pharmaceuticals, canalicular gel, prescription therapeutics, eye care products
Industry3 codes
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAJAL
Oculoplastics & Lacrimal Surgical Devices (Ptosis/Orbital Tools, DCR/Lacrimal Stents, Facial Implants)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAIADAF
Eye, Ear & Nasal Care
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Ophthalmic Goods Merchant Wholesalers423460
SIC code2 codes
  • Ophthalmic Goods3851
  • Surgical & Medical Instruments & Apparatus3841
Product category
Ophthalmic Pharmaceuticals
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1LACRIFILL Canalicular Gel Sales
TypeOne Time License
Description

Revenue generated from the sale of FDA-cleared LACRIFILL Canalicular Gel syringes for dry eye treatment. The product ships with cannulas in 10-pack cartons to eye care professionals in the United States.

mychesco.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1LACRIFILL
Description

LACRIFILL Canalicular Gel - FDA-cleared dry eye treatment therapy approved in May 2024 for temporarily blocking tear drainage. Product has treated over 100,000 patients in under two years.

mychesco.com
+1 more record
Core offering1 text field

Nordic Pharma manufactures and sells LACRIFILL Canalicular Gel, an FDA-cleared interventional ophthalmic gel delivered via prefilled syringes (now shipped with cannulas in 10-pack cartons) for the treatment of dry eye disease. The product temporarily blocks tear drainage as an alternative to traditional eye drops and is sold directly to eye care professionals and ophthalmologists in the U.S. market.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Over 100,000 patients treated in under two years since May 2024 launch
Product overview1 text field

Nordic Pharma offers a single unified product - LACRIFILL Canalicular Gel - an interventional dry eye treatment approach. The FDA-approved gel is delivered via prefilled syringes and works by temporarily blocking tear drainage to address dry eye disease affecting approximately 6.8 percent of U.S. adults. The company enhanced its offering in April 2026 by including cannulas with shipments based on physician feedback, improving provider convenience and patient experience.

Product and service1 record
1LACRIFILL Canalicular Gel
CategoryOphthalmic Pharmaceuticals / Dry Eye Treatment
Description

FDA-cleared canalicular gel for dry eye treatment that temporarily blocks tear drainage, delivered via prefilled syringes (now shipped with cannulas in 10-pack cartons) to eye care professionals and ophthalmologists in the United States.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

A leading global ophthalmic company selling surgical, vision care, and dry eye products (e.g., Systane family). Comparable as a broad incumbent that competes across multiple ocular surface touchpoints relevant to LACRIFILL's prescriber base.

TypeDirect peer
Description

Sells Xiidra (lifitegrast ophthalmic solution), a major prescription dry eye therapy competing head-to-head with LACRIFILL for ophthalmologist prescriptions in the U.S. dry eye market.

TypeBroad incumbent
Description

A major diversified ophthalmic company with both prescription (e.g., Vyzulta, ophthalmic surgical portfolio) and consumer dry eye products (artificial tears, ointments). Comparable because it addresses the same dry eye disease category with broader resources and an established U.S. commercial footprint.

TypeEmerging player
Description

Specialty ophthalmic company developing and commercializing therapies for rare ocular surface diseases, including dry eye indications. Comparable as a smaller, focused ophthalmic player competing in adjacent ocular surface categories.

5Sun Pharmaceutical Industries
TypeDirect peer
Description

Sells Cequa (cyclosporine A ophthalmic solution), a prescription dry eye therapy directly competing with LACRIFILL for ophthalmologist prescriptions and specialty pharmacy channel share in the U.S.

TypeDirect peer
Description

Markets Restasis (cyclosporine ophthalmic emulsion), the leading prescription dry eye therapy, and has deep relationships with U.S. ophthalmologists. Directly comparable because both compete for the same physician prescriber and dry eye patient population that LACRIFILL targets.

TypeEmerging player
Description

Commercial-stage ophthalmic company focused on interventional treatments for glaucoma and dry eye (e.g., TearCare). Comparable because it pursues procedure-based, interventional approaches in the ophthalmologist's office—a similar commercial model to LACRIFILL.

TypeEmerging player
Description

Developed and commercialized ophthalmic pharmaceuticals including dry eye therapies (e.g., Rocklatan and related pipeline) before being acquired by Alcon. Comparable as a specialty ophthalmic pharma with prescription dry eye franchise overlap.

TypeBroad incumbent
Description

Operates a large ophthalmic and vision care franchise including dry eye therapeutics and ocular surface products. Comparable as a broad incumbent with deep ophthalmologist relationships and resources that materially exceed Nordic Pharma's U.S. footprint.

TypeDirect peer
Description

Markets Tyrvaya (varenicline nasal spray) for dry eye disease and continues to develop ocular surface therapies through the Oyster Point franchise, targeting the same prescriber base and patient population as Nordic Pharma.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nordic Pharma

Ophthalmic Pharmaceuticalsnordicpharmagroup.com

Nordic Pharma is the U.S. arm of privately held Nordic Group, commercializing LACRIFILL Canalicular Gel — an FDA-cleared interventional dry eye therapy sold directly to ophthalmologists via enterprise field sales. The single-SKU product has treated over 100,000 U.S. patients since its May 2024 launch.

What Nordic Pharma does

Nordic Pharma, Inc. is the U.S. commercial arm of Nordic Group, a privately owned pan-European pharmaceutical company headquartered in Paris and founded in 1995. The U.S. entity is built around a single commercialized product, LACRIFILL Canalicular Gel, an FDA-cleared interventional therapy for dry eye disease that works by temporarily blocking tear drainage via a proprietary gel formulation delivered through prefilled syringes. The product received FDA clearance in May 2024 and was enhanced in April 2026 through the inclusion of cannulas in shipments, packaged in 10-pack cartons for direct distribution to U.S. eye care professionals.

The company has reported treating over 100,000 patients with LACRIFILL in under two years post-clearance, an adoption signal it actively promotes at specialty ophthalmology conferences including ASCRS 2026 in Washington D.C. Its go-to-market is an enterprise field sales motion targeting ophthalmologists, with quote-based pricing that is not publicly disclosed and a revenue model that functions as a one-time product sale per treatment. Leadership comprises Anders Lofgren (Founder, Managing Director & Vice President) and Jean-Michel Quinot (President). The firm operates as a privately held company with no disclosed institutional ownership, funding rounds, or M&A activity in the available record.

Nordic Pharma firmographics

Firmographics
Name
Nordic Pharma
Legal name
Nordic Pharma, Inc.
Website
https://nordicpharmagroup.com
Company type
Private
Founded year
1995
Operating status
Operating
Headcount range
101–250 employees
Short description
Nordic Pharma is the U.S. arm of privately held Nordic Group, commercializing LACRIFILL Canalicular Gel — an FDA-cleared interventional dry eye therapy sold directly to ophthalmologists via enterprise field sales. The single-SKU product has treated over 100,000 U.S. patients since its May 2024 launch.
Ownership category
akta.pro rank

Nordic Pharma industry classification

Industry
Product category
Ophthalmic Pharmaceuticals
NAICS
Ophthalmic Goods Manufacturing (339115), Ophthalmic Goods Merchant Wholesalers (423460)
SIC
Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAJAL
Oculoplastics & Lacrimal Surgical Devices (Ptosis/Orbital Tools, DCR/Lacrimal Stents, Facial Implants)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAIADAF
Eye, Ear & Nasal Care
Healthcare & Life Sciences/Pharmaceuticals/Over-the-Counter (OTC) Medicines

Keywords

  • Dry eye treatment
  • Ophthalmic pharmaceuticals
  • Canalicular gel
  • Prescription therapeutics
  • Eye care products

Where Nordic Pharma is headquartered

Location

Headquarters

HQ city
Hoofddorp
HQ country
Netherlands
HQ region
Europe

Markets served

Nordic Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. LACRIFILL Canalicular Gel Sales: Revenue generated from the sale of FDA-cleared LACRIFILL Canalicular Gel syringes for dry eye treatment. The product ships with cannulas in 10-pack cartons to eye care professionals in the United States.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Nordic Pharma product offering

Product offering

Core offering

Nordic Pharma manufactures and sells LACRIFILL Canalicular Gel, an FDA-cleared interventional ophthalmic gel delivered via prefilled syringes (now shipped with cannulas in 10-pack cartons) for the treatment of dry eye disease. The product temporarily blocks tear drainage as an alternative to traditional eye drops and is sold directly to eye care professionals and ophthalmologists in the U.S. market.

Product overview

Nordic Pharma offers a single unified product - LACRIFILL Canalicular Gel - an interventional dry eye treatment approach. The FDA-approved gel is delivered via prefilled syringes and works by temporarily blocking tear drainage to address dry eye disease affecting approximately 6.8 percent of U.S. adults. The company enhanced its offering in April 2026 by including cannulas with shipments based on physician feedback, improving provider convenience and patient experience.

Differentiator

Problem solved

Functional benefit

Brands

  • LACRIFILL: LACRIFILL Canalicular Gel - FDA-cleared dry eye treatment therapy approved in May 2024 for temporarily blocking tear drainage. Product has treated over 100,000 patients in under two years.
  • LACRIFILL Canalicular Gel

Products and services

  • LACRIFILL Canalicular Gel FDA-cleared canalicular gel for dry eye treatment that temporarily blocks tear drainage, delivered via prefilled syringes (now shipped with cannulas in 10-pack cartons) to eye care professionals and ophthalmologists in the United States.

Quantifiable outcome

  • Over 100,000 patients treated in under two years since May 2024 launch

Companies that use Nordic Pharma

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Nordic Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Nordic Pharma partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Nordic Pharma competitors and assessment

Company assessment

Broad incumbents

  • Alcon: A leading global ophthalmic company selling surgical, vision care, and dry eye products (e.g., Systane family). Comparable as a broad incumbent that competes across multiple ocular surface touchpoints relevant to LACRIFILL's prescriber base.
  • Bausch + Lomb: A major diversified ophthalmic company with both prescription (e.g., Vyzulta, ophthalmic surgical portfolio) and consumer dry eye products (artificial tears, ointments). Comparable because it addresses the same dry eye disease category with broader resources and an established U.S. commercial footprint.
  • Johnson & Johnson Vision: Operates a large ophthalmic and vision care franchise including dry eye therapeutics and ocular surface products. Comparable as a broad incumbent with deep ophthalmologist relationships and resources that materially exceed Nordic Pharma's U.S. footprint.

Direct peers

  • Novartis: Sells Xiidra (lifitegrast ophthalmic solution), a major prescription dry eye therapy competing head-to-head with LACRIFILL for ophthalmologist prescriptions in the U.S. dry eye market.
  • Sun Pharmaceutical Industries: Sells Cequa (cyclosporine A ophthalmic solution), a prescription dry eye therapy directly competing with LACRIFILL for ophthalmologist prescriptions and specialty pharmacy channel share in the U.S.
  • AbbVie (Allergan Aesthetics): Markets Restasis (cyclosporine ophthalmic emulsion), the leading prescription dry eye therapy, and has deep relationships with U.S. ophthalmologists. Directly comparable because both compete for the same physician prescriber and dry eye patient population that LACRIFILL targets.
  • Viatris (Oyster Point Pharma): Markets Tyrvaya (varenicline nasal spray) for dry eye disease and continues to develop ocular surface therapies through the Oyster Point franchise, targeting the same prescriber base and patient population as Nordic Pharma.

Emerging players

  • Kala Bio: Specialty ophthalmic company developing and commercializing therapies for rare ocular surface diseases, including dry eye indications. Comparable as a smaller, focused ophthalmic player competing in adjacent ocular surface categories.
  • Sight Sciences: Commercial-stage ophthalmic company focused on interventional treatments for glaucoma and dry eye (e.g., TearCare). Comparable because it pursues procedure-based, interventional approaches in the ophthalmologist's office—a similar commercial model to LACRIFILL.
  • Aerie Pharmaceuticals (Alcon): Developed and commercialized ophthalmic pharmaceuticals including dry eye therapies (e.g., Rocklatan and related pipeline) before being acquired by Alcon. Comparable as a specialty ophthalmic pharma with prescription dry eye franchise overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Nordic Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nordic Pharma leadership team

Management profile

Number of profiles

Profiles2 records

Nordic Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nordic Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nordic Pharma

What does Nordic Pharma do?

Nordic Pharma manufactures and sells LACRIFILL Canalicular Gel, an FDA-cleared interventional ophthalmic gel delivered via prefilled syringes (now shipped with cannulas in 10-pack cartons) for the treatment of dry eye disease. The product temporarily blocks tear drainage as an alternative to traditional eye drops and is sold directly to eye care professionals and ophthalmologists in the U.S. market.

Is Nordic Pharma a public or private company?

Nordic Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Nordic Pharma founded?

Nordic Pharma was founded in 1995. It employs 101 to 250 people.

Where is Nordic Pharma based?

Nordic Pharma is headquartered in Hoofddorp, Netherlands, in the Europe region.

How does Nordic Pharma make money?

One revenue line is on record: LACRIFILL Canalicular Gel Sales.

Who are Nordic Pharma's main competitors?

Broad incumbents on record are Alcon, Bausch + Lomb and Johnson & Johnson Vision. Direct peers are Novartis, Sun Pharmaceutical Industries, AbbVie (Allergan Aesthetics) and Viatris (Oyster Point Pharma). Emerging players are Kala Bio, Sight Sciences and Aerie Pharmaceuticals (Alcon).

Does Nordic Pharma have an API?

No public API is recorded for Nordic Pharma.

What industry is Nordic Pharma in?

Nordic Pharma's product category is Ophthalmic Pharmaceuticals. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts), with a secondary code of HLAHAJAL, Oculoplastics & Lacrimal Surgical Devices (Ptosis/Orbital Tools, DCR/Lacrimal Stents, Facial Implants). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePara celebrar el hito de 100.000 pacientes tratados, Nordic Pharma Inc. (EE.UU.) amplía su ofertaNordic Pharma, Inc. announced it is now including cannulas with its Lacrifill® canalicular gel shipments for dry eye treatment, having reached over 100,000 patients in under two years since its May 2024 FDA authorization. The expansion responds to physician feedback and marks a milestone for the company's interventional dry eye treatment approach. The company will conduct live demonstrations at the ASCRS annual meeting in Washington D.C. from April 10-13, 2026.PR NewswireMARKING MAJOR MILESTONE OF 100,000 PATIENTS TREATED, NORDIC PHARMA, INC. (U.S.) ENHANCES ITS OFFERING AND INCREASES PROVIDER CONVENIENCE BY INCLUDING CANNULAS WITH ITS SHIPMENTS OF LACRIFILL® CANALICUNordic Pharma, Inc. announced it is now including cannulas with shipments of its LACRIFILL Canalicular Gel, a dry eye treatment, in response to feedback from eye care professionals. The company has reached a milestone of treating over 100,000 patients with the product in less than two years since receiving FDA clearance in May 2024. The enhanced offering aims to improve provider convenience and support the growing adoption of the treatment for dry eye disease, which affects approximately 6.8 percent of US adults.PR NewswireNORDIC PHARMA, INC. ERREICHT MIT DER BEHANDLUNG VON 100.000 PATIENTEN EINEN WICHTIGEN MEILENSTEIN. (USA) ERWEITERT SEIN ANGEBOT UND ERHÖHT DEN BEDIENUNGSKOMFORT, INDEM ES SEINEN LIEFERUNGEN VON LACRIFNordic Pharma, Inc. announced it has treated over 100,000 patients with its LACRIFILL Canalicular Gel in less than two years since launching the dry eye treatment in the US market in May 2024. The company has expanded its product offering by including cannulas with its prefilled syringes based on positive physician feedback, shipping them in 10-pack cartons. The treatment, approved by the FDA for temporarily blocking tear drainage, addresses a condition affecting approximately 6.8 percent of US adults, with the company presenting live demonstrations at the ASCRS annual meeting in Washington, DC.PR NewswireMARKING MAJOR MILESTONE OF 100,000 PATIENTS TREATED, NORDIC PHARMA, INC. (U.S.) ENHANCES ITS OFFERING AND INCREASES PROVIDER CONVENIENCE BY INCLUDING CANNULAS WITH ITS SHIPMENTS OF LACRIFILL® CANALICUNordic Pharma, Inc. has begun shipping cannulas along with its LACRIFILL® Canalicular Gel syringes for dry eye treatment, enhancing its product offering in response to physician feedback. The company reached a major milestone of treating over 100,000 patients with the FDA-cleared gel in under two years since its May 2024 U.S. launch. The product addresses dry eye disease affecting approximately 6.8 percent of U.S. adults, and the company is showcasing the enhanced offering at the ASCRS annual meeting in Washington, D.C.Daily Medical NewsVIDEO: Lacrifill a reimbursable option for dry eye treatmentNordic Pharma Eye Care U.S. president Philip Gioia and chief commercial officer Jai G. Parekh discussed Lacrifill's launch and its impact on dry eye treatment. Lacrifill is reimbursed by CPT code 68761, and the procedure takes minutes with immediate onset of action.Business Wire BlogNordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United StatesAmring Pharmaceuticals, a Nordic Pharma subsidiary, completed its acquisition of Visant Medical, a dry eye disease device maker. The deal brings Visant's FDA-cleared LACRIFILL canalicular occlusive device to the U.S. market, with a planned 2024 launch. Nordic Pharma intends to seek global regulatory approval after the U.S. launch.PR NewswireEuropean Commission approves Teysuno in metastatic colorectal cancerThe European Commission approved a new indication for Teysuno (tegafur/gimeracil/oteracil) on January 24, 2022, for treating patients with metastatic colorectal cancer who cannot continue fluoropyrimidine treatment due to hand-foot syndrome or cardiotoxicity. Nordic Pharma received a positive CHMP opinion from EMA in December 2021 prior to this approval. Teysuno, an oral fluoropyrimidine licensed from Taiho Pharmaceutical in Japan, offers an alternative for patients needing to continue systemic treatment while managing these specific toxicities.PR NewswirePositive EMA opinion for the use of Teysuno in metastatic colorectal cancerNordic Pharma announced on January 4, 2022 that the CHMP adopted a positive opinion on December 16, 2021, recommending the expanded use of Teysuno for metastatic colorectal cancer patients who cannot continue fluoropyrimidine treatment due to hand-foot syndrome or cardiotoxicity. The drug, an oral fluoropyrimidine with an improved safety profile, was previously approved for advanced gastric cancer and has been on the European market since 2011 in 17 countries. The positive opinion is pending adoption by the European Commission, after which country-specific reimbursement applications will be required for patient access.